

Clodia Osipo
Publications

BeLow M, **Osipo C. Notch Signaling in Breast Cancer: A Role in Drug Resistance.** Cells. 2020 Sep 29;9(10):2204. doi: 10.3390/cells9102204. PMID: 33003540; PMCID: PMC7601482.

Peiffer DS, Ma E, Wyatt D, Albain KS, **Osipo C. DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development.** NPJ Breast Cancer. 2020 Aug 14;6:37. doi: 10.1038/s41523-020-00178-5. PMID: 32864429; PMCID: PMC7429502.

Peiffer DS, Wyatt D, Zlobin A, Piracha A, Ng J, Dingwall AK, Albain KS, **Osipo C. DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy.** Cancer Res. 2019 Oct 1;79(19):4965-4977. doi: 10.1158/0008-5472.CAN-19-1110. Epub 2019 Aug 6. PMID: 31387918; PMCID: PMC6774875.

Shah D, Wyatt D, Baker AT, Simms P, Peiffer DS, Fernandez M, Rakha E, Green A, Filipovic A, Miele L, **Osipo C. Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1.** Clin Cancer Res. 2018 Sep 15;24(18):4566-4578. doi: 10.1158/1078-0432.CCR-17-1952. Epub 2018 Jun 12. PMID: 29895705; PMCID: PMC6139046.

Baker A, Wyatt D, Bocchetta M, Li J, Filipovic A, Green A, Peiffer DS, Fuqua S, Miele L, Albain KS, **Osipo C. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.** Oncogene. 2018 Aug;37(33):4489-4504. doi: 10.1038/s41388-018-0251-y. Epub 2018 May 10. PMID: 29743588.

Fukushiro-Lopes DF, Hegel AD, Rao V, Wyatt D, Baker A, Breuer EK, **Osipo C, Zartman JJ, Burnette M, ..., Gentile S. Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer.** Oncotarget. 2017 Dec 4;9(3):3321-3337. doi: 10.18632/oncotarget.22925. PMID: 29423049; PMCID: PMC5790466.

Sobol A, Askonas C, Alani S, Weber MJ, Ananthanarayanan V, **Osipo C, Bocchetta M. Deubiquitinase OTUD6B Isoforms Are Important Regulators of Growth and Proliferation.** Mol Cancer Res. 2017 Feb;15(2):117-127. doi: 10.1158/1541-7786.MCR-16-0281-T. Epub 2016 Nov 18. PMID: 27864334; PMCID: PMC5290186.

Shah D, **Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far.** Genes Dis. 2016 Jun;3(2):114-123. doi: 10.1016/j.gendis.2016.02.002. Epub 2016 Feb 21. PMID: 30123819; PMCID: PMC6095671.

Nunes J, Zhang H, Angelopoulos N, Chhetri J, **Osipo C, Grothey A, Stebbing J, Giamas G. ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation.** Oncotarget. 2016 May 10;7(19):27599-612. doi: 10.18632/oncotarget.8504. PMID: 27050377; PMCID: PMC5053674.

Kim JL, Ha GH, Campo L, Denning MF, Patel TB, **Osipo C, Lin SY, Breuer EK. The role of Rak in the regulation of stability and function of BRCA1.** Oncotarget. 2015 Oct 14;8(49):86799-86815. doi: 10.18632/oncotarget.5717. PMID: 29156836; PMCID: PMC5689726.

Pandya K, Wyatt D, Gallagher B, Shah D, Baker A, Bloodworth J, Zlobin A, Pannuti A, Green A, ..., **Osipo C. PKC α Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.** Clin Cancer Res. 2016 Jan 1;22(1):175-86. doi: 10.1158/1078-0432.CCR-15-0179. Epub 2015 Sep 8. PMID: 26350262; PMCID: PMC4703529.

Das S, Sondarva G, Viswakarma N, Nair RS, **Osipo C**, Tzivion G, Rana B, Rana A. **Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.** J Biol Chem. 2015 Aug 28;290(35):21705-12. doi: 10.1074/jbc.M115.655563. Epub 2015 Jul 7. PMID: 26152725; PMCID: PMC4571892.

Baker AT, Zlobin A, **Osipo C. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.** Front Oncol. 2014 Dec 12;4:360. doi: 10.3389/fonc.2014.00360. PMID: 25566499; PMCID: PMC4264417.

Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MA, Franzen CA, Gupta GN, **Osipo C**, ..., Mi Z. **Osteopontin mediates an MZF1-TGF- β 1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.** Oncogene. 2015 Sep 10;34(37):4821-33. doi: 10.1038/onc.2014.410. Epub 2014 Dec 22. PMID: 25531323; PMCID: PMC4476970.

Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, ..., **Osipo C**, ..., Miele L. **Crosstalk between PKC α and Notch-4 in endocrine-resistant breast cancer cells.** Oncogenesis. 2013 Aug 5;2(8):e60. doi: 10.1038/oncsis.2013.26. PMID: 23917222; PMCID: PMC3759125.

Olsauskas-Kuprys R, Zlobin A, **Osipo C. Gamma secretase inhibitors of Notch signaling.** Onco Targets Ther. 2013 Jul 23;6:943-55. doi: 10.2147/OTT.S33766. PMID: 23901284; PMCID: PMC3726525.

Speiser JJ, Erşahin C, **Osipo C. The functional role of Notch signaling in triple-negative breast cancer.** Vitam Horm. 2013;93:277-306. doi: 10.1016/B978-0-12-416673-8.00013-7. PMID: 23810012.

Pekmezci M, Szpadarska A, **Osipo C**, Erşahin Ç. **Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.** Int J Surg Pathol. 2013 Apr;21(2):126-32. doi: 10.1177/1066896912467370. Epub 2012 Nov 30. PMID: 23204031.

Pekmezci M, Szpadarska A, **Osipo C**, Erşahin C. **The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma.** Patholog Res Int. 2012;2012:947041. doi: 10.1155/2012/947041. Epub 2012 Mar 11. PMID: 22482085; PMCID: PMC3317053.

Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, **Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.** Br J Cancer. 2011 Sep 6;105(6):796-806. doi: 10.1038/bjc.2011.321. Epub 2011 Aug 16. PMID: 21847123; PMCID: PMC3171020.

Clementz AG, Rogowski A, Pandya K, Miele L, **Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.** Breast Cancer Res. 2011 Jun 14;13(3):R63. doi: 10.1186/bcr2900. PMID: 21679465; PMCID: PMC3218952.

Pannuti A, Foreman K, Rizzo P, **Osipo C**, Golde T, Osborne B, Miele L. **Targeting Notch to target cancer stem cells**. Clin Cancer Res. 2010 Jun 15;16(12):3141-52. doi: 10.1158/1078-0432.CCR-09-2823. Epub 2010 Jun 8. PMID: 20530696; PMCID: PMC3008160.

Mehta K, **Osipo C**. **Trastuzumab resistance: role for Notch signaling**. ScientificWorldJournal. 2009 Dec 16;9:1438-48. doi: 10.1100/tsw.2009.166. PMID: 20024517; PMCID: PMC5823123.

Clementz AG, **Osipo C**. **Notch versus the proteasome: what is the target of gamma-secretase inhibitor-I?** Breast Cancer Res. 2009;11(5):110. doi: 10.1186/bcr2407. PMID: 19849815; PMCID: PMC2790851.

Hao L, Rizzo P, **Osipo C**, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L. **Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells**. Oncogene. 2010 Jan 14;29(2):201-13. doi: 10.1038/onc.2009.323. Epub 2009 Oct 19. PMID: 19838210; PMCID: PMC4976641.

Rizzo P, **Osipo C**, Pannuti A, Golde T, Osborne B, Miele L. **Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer**. Adv Enzyme Regul. 2009;49(1):134-41. doi: 10.1016/j.advenzreg.2009.01.008. Epub 2009 Jan 20. PMID: 19344631.

Rizzo P, **Osipo C**, Foreman K, Golde T, Osborne B, Miele L. **Rational targeting of Notch signaling in cancer**. Oncogene. 2008 Sep 1;27(38):5124-31. doi: 10.1038/onc.2008.226. PMID: 18758481.

Rizzo P, Miao H, D'Souza G, **Osipo C**, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, ..., Miele L. **Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches**. Cancer Res. 2008 Jul 1;68(13):5226-35. doi: 10.1158/0008-5472.CAN-07-5744. Erratum in: Cancer Res. 2008 Sep 1;68(17):7246. Song, Lynda L [added]. PMID: 18593923; PMCID: PMC4445363.

Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. **ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor**. Oncogene. 2008 Aug 28;27(37):5019-32. doi:10.1038/onc.2008.149. Epub 2008 May 12. PMID: 18469855.

Osipo C, Golde TE, Osborne BA, Miele LA. **Off the beaten pathway: the complex cross talk between Notch and NF-kappaB**. Lab Invest. 2008 Jan;88(1):11-7. doi: 10.1038/labinvest.3700700. Epub 2007 Dec 3. PMID: 18059366.

Paunesku T, Vogt S, Lai B, Maser J, Stojićević N, Thurn KT, **Osipo C**, Liu H, Legnini D, Wang Z, Lee C, Woloschak GE. **Intracellular distribution of TiO₂-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity**. Nano Lett. 2007 Mar;7(3):596-601. doi: 10.1021/nl0624723. Epub 2007 Feb 3. PMID: 17274661; PMCID: PMC3651270.

Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. **Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer**. Int J Oncol. 2007 Feb;30(2):509-20. PMID: 17203234.

Liu H, Cheng D, Weichel AK, **Osipo C**, Wing LK, Chen B, Louis TE, Jordan VC. **Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells**. Int J Oncol. 2006 Nov;29(5):1237-46. PMID: 17016657.

O'Regan RM, **Osipo C**, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. **Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.** Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2255-63. doi: 10.1158/1078-0432.CCR-05-2584. PMID: 16609042.

Osipo C, Miele L. **Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC.** Cancer Biol Ther. 2006 Feb;5(2):238-9. doi: 10.4161/cbt.5.2.2566. Epub 2006 Feb 7. PMID: 16552173.

Lewis JS, Meeke K, **Osipo C**, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC. **Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.** J Natl Cancer Inst. 2005 Dec 7;97(23):1746-59. doi: 10.1093/jnci/dji400. PMID: 16333030.

Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, **Osipo C**, Jordan VC, Volpert OV, Satcher RL Jr, Gartenhaus RB. **MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.** Cancer Res. 2005 Dec 1;65(23):10651-6. doi: 10.1158/0008-5472.CAN-05-0845. PMID: 16322206.

Jordan VC, Lewis JS, **Osipo C**, Cheng D. **The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.** Breast. 2005 Dec;14(6):624-30. doi: 10.1016/j.breast.2005.08.022. Epub 2005 Oct 3. PMID: 16202599.

Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC. **Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.** Cancer Res. 2005 Sep 15;65(18):8504-13. doi: 10.1158/0008-5472.CAN-04-4107. PMID: 16166331.

Lewis JS, **Osipo C**, Meeke K, Jordan VC. **Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.** J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):131-41. doi: 10.1016/j.jsbmb.2004.12.032. Epub 2005 Feb 8. PMID: 15862958.

Osipo C, Gajdos C, Cheng D, Jordan VC. **Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.** J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):249-56. doi: 10.1016/j.jsbmb.2004.12.005. PMID: 15860267.

Osipo C, Liu H, Meeke K, Jordan VC. **The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.** Exp Biol Med (Maywood). 2004 Sep;229(8):722-31. doi: 10.1177/153537020422900804. PMID: 15337826.

Jordan VC, **Osipo C**, Schafer JM, Fox JE, Cheng D, Liu H. **Changing role of the oestrogen receptor in the life and death of breast cancer cells.** Breast. 2003 Dec;12(6):432-41. doi: 10.1016/s0960-9776(03)00149-8. PMID: 14659118.

Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. **Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.** J Natl Cancer Inst. 2003 Nov 5;95(21):1597-608. doi: 10.1093/jnci/djg079. PMID: 14600092.

Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, **Osipo C**, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC. **Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.** J Natl Cancer Inst. 2003 Nov 5;95(21):1586-97. doi: 10.1093/jnci/djg080. PMID: 14600091.

Dardes RC, Schafer JM, Pearce ST, **Osipo C**, Chen B, Jordan VC. **Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.** Gynecol Oncol. 2002 Jun;85(3):498-506. doi: 10.1006/gyno.2002.6659. PMID: 12051881.

Osipo C, Dorman S, Frankfater A. **Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors.** Exp Cell Res. 2001 Apr 1;264(2):388-96. doi: 10.1006/excr.2000.5121. PMID: 11262195.